Cabergoline effect on blood sugar in type 2 diabetic patients with oral agent failure.
Ergot-derived dopamine D2 receptor agonists are the usual treatment of hyperprolactinemia and Parkinson's disease and recently bromocriptine has been approved for the treatment of type 2 diabetes. The aim of this study was the evaluation of short-term effect of cabergoline in poorly controlled diabetic patients with oral agent failure who refused insulin therapy.


METHODS
This study was performed in 17 overweight women and men with type 2 diabetes with persistent hyperglycemia in spite of treatment with maximum dose of sulfonylurea, metformin and pioglitazone. 10 patients (group I) randomized to be treated with cabergoline 0.5 mg weekly for 3 months and 7 patients (group II) with placebo. Fasting and postprandial plasma glucose concentration and HbAlc measured in beginning and end of the study.


RESULTS
FBS decreased from 210.70 +/- 21.29 to 144.90 +/- 26.56 mg/dl in cabergoline group whereas it decreased in placebo group insignificantly. Postprandial blood glucose decreased from 264.2 +/- 28 mg/dl to 203.6 +/- 34.34 mg/dl in cabergoline group whereas it increased in placebo group insignificantly. HbA1c decreased in cabergoline group from 8.48 +/- 0.44 to 7.7 +/- 0.11 whereas in control group it increased insignificantly from 8.7 +/- 0.33 to 8.8 +/- 0.16.


CONCLUSIONS
Cabergoline improves glycemic control in type 2 diabetic patients with oral agent failure. It reduces both fasting and postprandial plasma glucose levels and causes 0.45-1.11 reduction in HbA1c.
Mashhad Medical University, Endocrinology, Ahmad Abad, Mashhad, Khorasan 9187883655 Iran, Islamic Republic Of. taghavimr@mums.ac.ir
Seyyed Morteza
SM
Taghavi
Seyyede Sedighe
SS
Fatemi
Hale
H
Rokni
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D000077465:Cabergoline; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017211:Treatment Failure
D001786:Blood Glucose; D000077465:Cabergoline; D018491:Dopamine Agonists; D004873:Ergolines; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents